Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infiltrating Lymphocytes and the Degree of Desmoplasia

Tancoš, Vladimír; Grendár, Marian; Farkašová, Anna; Huťka, Zdenko; Kviatkovská, Zuzana

doi:10.14735/amko202055

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Muller et al, ADC shows increased signalling through TYK2, which transmits signalling through interferons and has more phosphorylation of STAT3 than SCCs. SCCs have less TYK2 and p-STAT3 due to increased proteasomal degradation of TYK2 by an E3 ubiquitin ligase called SIAH2 [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

Simundza

Krnić

Juričić

et al. 2021

JPM

View full text Add to dashboard Cite

The aim of this study was to analyse the expression of PD-L1 in non-small cell lung cancer (NSCLC) and its correlation with immune microenvironment response (IMR), clinic-pathological parameters, and outcome. The sample included 76 male and 32 female patients who underwent surgical resection. The mean age of the males was 66 years, and that of the females was 64 years. Adenocarcinoma (ADC) was diagnosed in 68 (63%) cases, squamous cell carcinoma in 35 (32%) cases, and NSCLC (not otherwise specified) in 5 (5%) cases. Metastatic lymph nodes were found in 38 (36%) patients, 18 with N1 nodes and 20 with N2 nodes. PD-L1 expression was valuated as the percentage of positive cancer cells among all cancer cells. Gender, age, and histologic type were not associated with PD-L1 expression (all p > 0.05). The subtypes of ADC were associated with PD-L1 expression (p = 0.050). The papillary subtype was 4.3 times more common among PD-L1 negative than PD-L1 positive ADC; the solid subtype was 1.9 times more common among PD-L1 positive than PD-L1 negative ADC. IMR was predominantly strong in 19 cases, weak in 36, and absent in 53 cases. The median value of PD-L1 expression in cancer cells was positively correlated with IMR (p = 0.039). PD-L1 expression was not correlated with overall survival (p = 0.643). The patients with strong, inflammatory-like IMR had an average survival time that was 12 months longer than patients with absent/low IMR (LR = 2.8; p = 0.132). In conclusion, the papillary subtype was more commonly PD-L1 negative in comparison with other subtypes of ADC. Positive PD-L1 expression in tumour cells was connected with strong, inflammatory-like IMR. Patients with strong IMR tended to experience better outcomes. Further investigations are needed on larger-scale cohorts to elucidate the insights of this descriptive study.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

Simundza

Krnić

Juričić

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully

Lin

et al. 2020

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report

Wang

Xiao

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

We previously demonstrated that a transforming growth factor β type II receptor (TGFBR2) mutation can predict resistance to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC), based on publicly available immunotherapeutic cohorts. However, the efficacy of ICI-based regimens in patients with advanced NSCLC harboring TGFBR2 mutations in the real-world setting is rarely reported. The present study describes the case of a patient with advanced NSCLC who harbors a TGFBR2 mutation. The patient was treated with ICI monotherapy and experienced hyperprogressive disease (HPD). The clinical information was retrospectively collected. The progression-free survival (PFS) was only 1.3 months. In conclusion, HPD occurred in a patient with advanced NSCLC with a TGFBR2 mutation who received an ICI monotherapy regimen. The findings suggested that caution may be required regarding the clinical delivery of ICI monotherapy to patients with NSCLC and TGFBR2 mutations; ICIs combined with chemotherapy may be an alternative treatment option.

show abstract

Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infiltrating Lymphocytes and the Degree of Desmoplasia

Cited by 3 publications

References 23 publications

Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer

Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully

Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report

Contact Info

Product

Resources

About